RITUXIMAB IN PEDIATRIC RHEUMATOLOGY

<p><em>The article presents literature review on the role of B-lymphocytes in pathogenesis of rheumatologic diseases and on the administration of chimeric anti-CD20 monoclonal antibodies — rituximab — for treatment of systemic lupus erythematosus, systemic vasculitis, juvenile dermatomyo...

Full description

Bibliographic Details
Main Authors: E.I. Alexeeva, R.V. Denisova, S.I. Valieva, T.M. Bzarova, A.O. Lisitsyn
Format: Article
Language:English
Published: "Paediatrician" Publishers LLC 2010-01-01
Series:Вопросы современной педиатрии
Online Access:http://vsp.spr-journal.ru:80/jour/article/view/891
Description
Summary:<p><em>The article presents literature review on the role of B-lymphocytes in pathogenesis of rheumatologic diseases and on the administration of chimeric anti-CD20 monoclonal antibodies — rituximab — for treatment of systemic lupus erythematosus, systemic vasculitis, juvenile dermatomyositis, and juvenile arthritis in children. Results of studies showed that rituximab has good tolerability, efficacy and safety in children’s rheumatologic practice.</em><strong><em></em></strong></p><p><strong><em>Key words: children, B-lymphocytes, rituximab, treatment, depletion.</em></strong><br /><span style="text-decoration: underline;"><em>(<em><em>Voprosy sovremennoi pediatrii — </em></em>Current Pediatrics. – 2010;9(3):<em>54-62</em>)</em></span></p>
ISSN:1682-5527
1682-5535